Photoreactivity of indirubin derivatives

Photochemical and Photobiological Sciences

Volumn 7, Issue 3, 2008, Pages 328-336

  Olivier, David ^a   Poincelot, Marie Anne ^a   Douillard, Samuel ^a   Lefevre, Carine ^a   Moureau, Julien ^a   Ferandin, Yoan ^b   Bettayeb, Karima ^b   Xiao, Zhijian ^c   Magiatis, Prokopios ^d   Skaltsounis, Leandros ^d   Meijer, Laurent ^b   Patrice, Thierry ^a  

^a HGRL   (France)

^b STATION BIOLOGIQUE   (France)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INDIRUBIN; PHOSPHOTRANSFERASE INHIBITOR; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ARTICLE; BLOOD FLOW; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FETAL CALF SERUM; FLUORESCENCE; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOREACTIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; RAT;

MURINAE;

EID: 41849136118     PISSN: 1474905X     EISSN: 14749092     Source Type: Journal    
DOI: 10.1039/b711261k     Document Type: Article

References (37)

1. C. J. Cooksey Tyrian purple: 6.6′-Dibromoindigo and related compounds Molecules 2001 6 736 769
2. L. Meijer N. Guyard, L. A. Skaltsounis and G. Eisenbrand, Indirubin, the red shade of indigo, Life in Progress, Roscoff, France, 2006
3. R. Hoessel S. Leclerc J. A. Endicott M. E. Nobel A. Lawrie P. Tunnah M. Leost E. Damiens D. Marie D. Marko E. Niederberger W. Tang G. Eisenbrand L. Meijer Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases Nat. Cell Biol. 1999 1 60 67
4. Z. Xiao Y. Hao B. Liu L. Qian Indirubin and mesoindigo in the treatment of chronic myelogenous leukemia in China Leuk. Lymphoma 2002 43 1763 1768
5. M. Knockaert M. Blondel S. Bach M. Leost C. Elbi G. L. Hager S. R. Nagy D. Han M. Denison M. French X. P. Ryan P. Magiatis P. Polychronopoulos P. Greengard L. Skaltsounis L. Meijer Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins Oncogene 2004 23 4400 4412
6. D. Marko S. Schatzle A. Friedel A. Genzlinger H. Zankl L. Meijer G. Eisenbrand Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells Br. J. Cancer 2001 84 283 289
7. S. Leclerc M. Garnier R. Hoessel D. Marko J. A. Bibb G. L. Snyder P. Greengard J. Biernat E.-M. Mandelkow G. Eisenbrand L. Meijer cogen synthase kinase-3(Beta) and CDK5/p25, two kinases involved in abnormal tauphosphorylation in Alzeimer's disease - A property common to most CDK inhibitors? J. Biol. Chem. 2001 276 251 260
8. L. H. Tsai M. S. Lee J. Cruz Cdk5, a therapeutic target for Alzheimer's disease? Biochim. Biophys. Acta 2004 1697 137 142
9. P. D. Smith M. J. O'Hare D. S. Park CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease Trends Mol. Med. 2004 10 445 451
10. M. Zhang J. Li P. Chakrabarty B. Bu I. Vincent Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice Am. J. Pathol. 2004 165 843 853
11. J. Wang S. H. Liu Y. P. Fu J. H. Wang Y. M. Lu Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors Nat. Neurosci. 2003 6 1039 1047
12. S. Di Giovanni V. Movsesyan F. Ahmed I. Cernak S. Schinelli B. Stoica A. I. Faden Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury Proc. Natl. Acad. Sci. USA 2005 102 8333 8339
13. A. G. Rossi D. A. Sawatzky A. Walker C. Ward T. A. Sheldrake N. A. Riley A. Caldicott M. Martinez-Losa T. R. Walker R. Duffin M. Gray E. Crescenzi M. C. Martin H. J. Brady J. S. Savill I. Dransfield C. Haslett Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis Nat. Med. 2006 12 1056 1064
14. F. Y. Wei K. Nagashima T. Ohshima Y. Saheki Lu YF M. Matsushita Y. Yamada K. Mikoshiba Y. Seino H. Matsui K. Tomizawa Cdk5-dependent regulation of glucose-stimulated insulin secretion Nat. Med. 2005 11 1104 1108
15. E. Damiens; B. Baratte D. Marie G. Eisenbrand L. Meijer Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest Oncogene 2001 20 3786 3797
16. M. N. Kosmopolou D. D. Leonidas E. D. Chysina N. Bischler G. Eisenbrand C. E. Sakarellos R. Pauptit N. G. Oikonomakos Binding of the potential antitumour agent indirubin-5-sulfonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to PCDK2-cycling A complex Eur. J. Biochem. 2004 271 2280 2290
17. Y. Ferandin K. Bettayeb M. Kritsanida O. Lozach P. Polychronopoulos P. Magiatis A. L. Skaltsounis L. Meijer 3′ substituted 7-halogenoindirubins, a new class of cell death-inducing agents J. Med. Chem. 2006 49 4638 4649
18. L. Bourré G. Simonneaux Y. Ferrand S. Thibaut Y. Lajat T. Patrice Synthesis, in vitro and in vivo evaluation of a diphenylchlorin sensitizer for photodynamic therapy J. Photochem. Photobiol., B 2003 69 179 192
19. R. F. Barth Rat brain tumor models in experimental neuro-oncology: The 9 L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 Gliomas J. Neuro-Oncol. 1998 36 91 102
20. J. Ribas K. Bettayeb Y. Ferandin M. Knockaert X. Garrofé-Ochoa F. Totzke C. Schächtele J. Mester P. Polychronopoulos P. Magiatis A. L. Skaltsounis J. Boix L. Meijer 7-Bromoindirubin-3′-oxyme induces caspase-independent cell death Oncogene 2006 25 6304 6318
21. P. Polychonopoulos P. Magiatis L. Skaltsounis V. Myrianthopoulos E. Mikros A. Tarricone A. Musacchio S. M. Roe L. Pearl M. Leost P. Greengard L. Meijer Med. Chem. 2004 47 935 94
22. A. Beauchard Y. Ferrandin S. Frère O. Lozach M. Blairvacq L. Meijer V. Thiéry T. Besson Synthesis of novel 5- substituted indirubins as potential inhibitor of protein kinases Bioorg. Med. Chem. 2006 14 6434 6443
23. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983 65 55 63
24. J. Ribas J. Boix Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs Exp. Cell Res. 2004 295 9 24
25. H. Eldar-Finkelman Glycogen synthase kinase 3: an emerging therapeutic target Trends Mol. Med. 2002 8 3 126 32
26. L. Meijer A. L. Skaltsounis P. Magiatis P. Polychronopoulos M. Knockaert M. Leost X. P. Ryan C. A. Vonica A. Brivanlou R. Dajani C. Crovace C. Tarricone A. Musacchio S. M. Roe L. Pearl P. Greengard GSK-3-selective inhibitors derived from Tyrian purple indirubins Chem. Biol. 2003 10 1255 66
27. K. R. Weishaupt C. J. Gomer T. J. Dougherty Identification of singlet oxygen as the cytotoxic agent in photoinactivation of murine tumors Cancer Res. 1976 36 2326 2329
28. A. W. Girotti Mechanism of lipid peroxidation J. Free Radicals Biol. Med. 1985 1 87 95
29. C. Tanielian R. Mechin R. Seghrouchni C. Schweitzer Mechanistic and kinetic aspects of photosensitization in the presence of oxygen Photochem. Photobiol. 2000 71 12 19
30. M. A. Biel Photodynamic therapy and the treatment of head and neck cancers J. Clin. Laser Med. Surg. 1996 14 239 244
31. H. Kostron A. Obwegeser R. Jakober Photodynamic therapy in neurosurgery: A review J. Photochem. Photobiol., B 1997 36 157 168
32. T. Patrice D. Olivier L. Bourre Photodynamic therapy in clinics: indications, results, markets J. Environ. Pathol. Toxicol. Oncol. 2006 25 467 487
33. R. M. Christie, Indirubin: the relationship between chemical structure and physical properties, with particular reference to colour, in Indirubin, the red shade of indigo, ed., L. Meijer,,, N. Guyard,,, L. A. Skaltsounis, and, G. Eisenbrand,, Life in Progress, Roscoff, France, 2006, pp. 103-188
34. L. Ko A. Koestner W. Wechsler Morphological characterization of nitrosouera-induced glioma cell lines and clones Acta Neuropathol. 1980 51 23 31
35. J. C. Tom Model systems in neurooncology Acta Neurchir. 2002 83 79 83
36. M. G. del Carmen I. Rizvi Y. Chang A. C. Moor E. Oliva M. Sherwood B. Pogue T. Hasan Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo J. Natl. Cancer Inst. 2005 97 1516 1524
37. F. Jiang K. K. Cho T. Mikkelse L. Tong Y. S. Lew N. Hochbaum J. Shargorodsky M. Chop Tamoxifen increases photodynamic therapeutic response of U87 and U25 in human glioma cells J. Neuro-Oncol. 2002 56 51 58